# Seroprevalence of anti-SARS coronavirus 2 antibodies in Thai adults during the first three epidemic waves

3

Hatairat Lerdsamran<sup>1</sup>, Anek Mungaomklang<sup>2</sup>, Sopon Iamsirithaworn<sup>3</sup>, Jarunee Prasertsopon<sup>1</sup>,
Witthawat Wiriyarat<sup>4</sup>, Suthee Saritsiri<sup>5</sup>, Ratikorn Anusorntanawat<sup>6</sup>, Nirada Siriyakorn<sup>7</sup>, Poj
Intalapaporn<sup>7</sup>, Somrak Sirikhetkon<sup>2</sup>, Kantima Sangsiriwut<sup>8</sup>, Worawat Dangsakul<sup>9</sup>, Suteema
Sawadpongpan<sup>1</sup>, Nattakan Thinpan<sup>1</sup>, Pilailuk Okada<sup>9</sup>, Ranida Techasuwanna<sup>3</sup>, Noparat
Mongkalangoon<sup>3</sup>, Kriengkrai Prasert<sup>10</sup>, Pilaipan Puthavathana<sup>1\*</sup>

9

<sup>1</sup> Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand

<sup>11</sup> <sup>2</sup> Institute for Urban Disease Control and Prevention, Department of Disease Control, Ministry of

12 Public Health, Bangkok, Thailand

<sup>3</sup> Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

<sup>4</sup> Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand

<sup>5</sup> The 67<sup>th</sup> Public Health Center Thaweewatthana, Department of Health, Bangkok Metropolitan

16 Administration, Bangkok, Thailand

<sup>6</sup> Chaophraya Yommarat Hospital, Office of the Permanent Secretary, Ministry of Public Health,

- 18 Suphanburi, Thailand
- <sup>7</sup> Rajavithi Hospital, Department of Medical Services, Ministry of Public Health, Bangkok,
  Thailand
- <sup>8</sup> Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol
- 22 University, Bangkok, Thailand

23	<sup>9</sup> Department of Medical Science, Ministry of Public Health, Nonthaburi, Thailand
24	<sup>10</sup> Nakhon Phanom Provincial Hospital, Department of Medical Services, Ministry of Public
25	Health, Nakhon Phanom, Thailand
26	
27	*Corresponding author
28	E-mail: pilaipan.put@mahidol.edu (PP)

29

## 30 Abstract

This study sought to determine the anti-SARS-CoV-2 antibody status of 4111 Thai people from 31 32 May 2020 to April 2021, a period which spanned the first two and part of the third epidemic wave of the COVID-19 in Thailand. Participants comprised 142 COVID-19 patients, 2113 individuals 33 34 at risk due to their occupations [health personnel, airport officers, public transport drivers, and 35 workers in entertainment venues (pubs, bars and massage parlors)], 1856 individuals at risk due to sharing workplaces or living communities with COVID-19 patients, and 553 Thai citizens 36 returning after extended periods in countries with a high disease prevalence. All sera were tested 37 in a microneutralization assay and a chemiluminescence immunoassay (CLIA) for IgG against the 38 N protein. Furthermore, we performed an immunofluorescence assay to resolve discordant results 39 between the two assays. Antibody responses developed in 88% (15 of 17) of COVID-19 patients 40 at 8 days and in 94-100% between 15 and 60 days after disease onset. Neutralizing antibodies 41 persisted for at least 8 months, longer than the IgG did, against the N protein. None of the health 42 43 providers, airport officers, and public transport drivers were seropositive, while the antibodies were present in 0.44% of entertainment workers. This study showed the seropositivity of 1.9, 1.5, 44 and 7.5% during the 3 epidemic waves, respectively, in Bangkok residents who were at risk due 45

to sharing workplaces or communities with COVID-19 patients. Also, antibody prevalence was
1.3% in Chiang Mai people during the first epidemic wave, and varied between 6.5 and 47.0% in
Thais returning from high-risk countries. This serosurveillance study found a low infection rate of
SARS-CoV-2 in Thailand before the emergence of the Delta variant in late May 2021. The findings
support the Ministry of Public Health's data, which are based on numbers of patients and contact
tracing.

Key words: SARS-coronavirus-2, seroepidemiology, microneutralization assay, ELISA,
chemiluminescence assay, immunofluorescence assay, Thailand

54

## 55 Introduction

On 13 January 2020, Thailand was the first country to report a confirmed coronavirus disease-19 (COVID-19) case outside of China. The first indigenous case in Thailand occurred on 30 January 2020 in a local taxi driver who had no history of traveling abroad; investigation suggested that he was exposed to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by a group of Chinese tourist passengers [1]. As of November 2021, Thailand had experienced 4 epidemic waves associated with different SARS-CoV-2 variants which emerged during the pandemic (Fig 1).

63

Fig 1. Situation of SARS-CoV-2 infection in Thailand during March 1, 2020 through
December 21, 2021.

66

67 According to the Department of Disease Control (DDC), Ministry of Public Health 68 (MOPH), the first epidemic wave began in January 2020, peaked in March-April, gradually

declined, and ended on 14 December 2020. Large clusters occurring during this wave had linkages 69 with attending boxing stadiums or entertainment venues in Bangkok. The strains causing this wave 70 belonged to clades L, S, O, V, and G likely reflecting multiple introductions of virus into the 71 country through tourism. The second wave was shorter, lasting from 15 December 2020 to 31 72 73 March 2021. This epidemic wave began among Myanmar migrant workers in a seafood market in 74 Mahachai District, Samut Sakorn Province, 37 km south of Bangkok. The causative virus belonged to the GH clade (G614 mutation) which was circulating in Myanmar during the second epidemic 75 wave since August 2020 [2]. The third epidemic wave in Thailand began on 1 April 2021, again 76 77 in nightlife entertainment venues, and might be linked to the introduction of the Alpha variant (B.1.1.7) by the Thai people returning from Cambodia in the middle of March 2021 [3]. The Alpha 78 79 variant had spread throughout Cambodia, particularly in Phnom Penh, since February 2021 [4]. The Alpha variant spread to many parts of Thailand in the second week of April due to movement 80 of large numbers of people during the annual Songkran or water festival (the traditional Thai new 81 82 year). Subsequently, the Delta variant, first detected among workers in a big construction camp at Laksi, Bangkok, on 7 May 2021 [5], spread countrywide seeding the fourth epidemic wave and 83 caused loss of control of the epidemic. 84

People infected with SARS-CoV-2 may develop antibodies targeting multiple viral proteins, regardless of whether they have symptoms or not. Therefore, serosurveillance was an important tool for estimating the magnitude and monitoring the epidemic, especially since asymptomatic cases were common. A meta-analysis showed that the as many as 35% of cases were asymptomatic [6]. Serological data can also show the duration of antibody responses to COVID-19 infection, indicating partial protection from re-infection. Studies in Europe and the US have shown that neutralizing antibodies persist in a majority of COVID-19 cases for up to 13 months

92 after infection [7], and patients with severe disease exhibited a higher level of neutralizing 93 antibodies than those with milder disease symptoms [8]. The present study conducted a cross-94 sectional serosurveillance of anti-SARS-CoV-2 in Thai people in various risk groups in Bangkok 95 and Chiang Mai Province from May 2020 to May 2021 (the duration spanned the first, second, 96 and part of the third epidemic waves). The serological techniques used in this study included a 97 microneutralization (microNT) assay, a chemiluminescence immunoassay (CLIA), and an indirect 98 immunofluorescence assay (IFA).

99

# **100** Material and methods

## 101 Ethical statement

Usage of human sera from participants of age older than 18 received approval from the
 Mahidol University Central Institutional Review Board (MU-CIRB) under protocol number MU COVID2020.001/2503.

## 105 Study sites

Bangkok, the capital of Thailand, and Chiang Mai Province, 696 km north of Bangkok, were chosen as study sites due to their popularity as travel destinations, high population densities, and the high numbers of SARS-CoV-2-infected cases.

## **109** Study population

The study involved 4111 serum samples from 4 groups of participants, as follows. 1) Anonymized archival serum samples from COVID-19 patients with no information of disease severity (Sera were the leftover samples from clinical laboratory investigations). 2) People at risk due to their occupations (health personnel, airport drivers, public transport drivers, and workers in

entertainment venues (e.g., pubs, bars, and massage parlors). 3) People at risk due to sharing 114 workplaces or communities with COVID-19 patients. In the enrollment process for participants in 115 groups 2 and 3, epidemiologists explained the purpose of the study to obtain written consent for 116 interviewing about their demographics, occupation, workplace, residence, and general health 117 condition, including a donation of 5-8 ml of blood, with specimens labeled using ID codes. 4) Thai 118 119 citizens in state quarantines, when arrived Thailand after extended duties in countries with known SARS-CoV-2 outbreaks. Blood specimens were collected for anti-SARS-CoV-2 antibody testing 120 [along with real-time reverse transcription-polymerase chain reaction (RT-PCR)] to support active 121 122 case surveillance activities conducted by the Institute for Urban Disease Control and Prevention (IUDC), DDC, MoPH. For this group, an ethical review was waived under the authorization of the 123 DDC, MOPH, as part of the emergency public health response to the pandemic. Nevertheless, 124 participants received explanations and gave verbal consent. 125

#### Cell and virus cultivation 126

We cultivated Vero cells (African green monkey kidney cells - ATCC, CCL-81) in Eagle's 127 minimum essential medium (EMEM) (Gibco, NY) supplemented with 10% fetal bovine serum 128 129 (FBS) (Gibco, NY), penicillin, gentamycin, and amphotericin B. SARS-CoV-2 was isolated and propagated in Vero cells maintained in EMEM supplemented with 2% FBS in a Biosafety 130 Laboratory Level-3 facility. Using the Reed-Muench method, we calculated the virus 131 132 concentration for 50% tissue culture infective dose (TCID50) for further use in the microNT assay.

#### **Test viruses** 133

This study used 3 SARS-CoV-2 isolates as test viruses in the microNT assay. The purpose 134 of doing so was to match the circulating virus at the time of blood specimen collection. The SARS-135 CoV-2 isolate designated hCoV-19/Thailand/MUMT-4/2020, clade O (GISAID accession number 136

EPI ISL 493139) was used as the test virus for sera collected during the first epidemic wave, 137 while hCoV-19/Thailand/MUMT-13/2021, clade GH (GISAID accession 138 number EPI ISL 6267810), and hCoV-19/Thailand/MUMT-36/2021, clade GRY (B.1.1.7) (GISAID 139 accession number EPI ISL 6267895) were used as the test viruses for the second and third 140 epidemic waves, respectively. 141

#### 142 **Experimental design**

This study employed the microNT assay and CLIA to detect anti-SARS antibodies in each test serum. When results of the two assays were concordant, the test serum was considered positive or negative for anti-SARS antibodies. In case of discordant results, the test serum was further investigated by IFA.

## 147 Microneutralization assay

We used the cytopathic effect (CPE)-based MicroNT assay to determine levels of 148 neutralizing (NT) antibodies against SARS-CoV-2 in the test sera. The assay employed Vero cell 149 monolayers in 96-well microculture plates and SARS-CoV-2 at a final concentration of 100 150 151 TCID50/100 µl as the test virus. The method followed those described in our previous studies [9, 10]. Briefly, the test serum was heat-inactivated and serially two-fold diluted from 1:10 to 1:1280. 152 A 60 µl volume of each serum dilution was mixed with 60 µl of the test virus at a concentration of 153 200 TCID50/100 µl. After an hour of incubation at 37 °C, a 100 µl volume of the virus-serum 154 mixture was inoculated in duplicate into wells containing the Vero cell monolayer. The reaction 155 plates were incubated at 37 °C for 3 days before reading the results. We defined the NT antibody 156 titer as the highest reciprocal serum dilution that inhibited >50% CPE in the wells inoculated with 157 the serum-virus mixture compared to wells with the uninfected cell control. A titer of 10 or greater 158 was considered positive for NT antibody. 159

## 160 Chemiluminescence immunoassay

CLIA using Architect auto-analyzer (Abbott Laboratories, USA) is the two-step, fully 161 automated immunoassay that qualitatively detected binding between the SARS-CoV-2 162 nucleoprotein (N) antigen coated on paramagnetic microparticles and human IgG in the test sera. 163 The assay required a minimal volume of 150 µl of test serum to fill the reaction cup. Acridinium-164 conjugated anti-human IgG bound the human IgG and then emitted chemiluminescence signals 165 quantitated as a relative light units (RLUs). It took about 1 hour to complete a test run. The level 166 of SARS-CoV-2 IgG was directly correlated to the amount of RLUs. An index value was 167 established based on the ratio between the RLU of the kit positive sample (S) and the calibrator 168 (C). A test serum with an S/C ratio  $\geq$ 1.4 was considered positive for the SARS-CoV-2 IgG. 169

### 170 Indirect immunofluorescence assay

171 The IFA staining method was previously described [10]. The assay employed SARS-CoV-2-infected Vero cells deposited on microscopic slides as the test antigens. To standardize the test 172 antigen given the lot-to-lot variation, 50-75% of the infected cells must express N and spike (S1) 173 174 proteins when stained with specific monoclonal antibodies (Sino Biological, Beijing, China). Human serum at a dilution of 1:10 in phosphate-buffered saline was incubated with the infected 175 cell for 60 minutes at 37 °C and followed by addition of polyclonal rabbit anti-human IgA, IgG, 176 IgM, Kappa, and Lambda conjugated with fluorescein isothiocyanate (Dako, Glostrup, Denmark) 177 in Evan's blue solution for 60 minutes. The stained viral antigens in the cytoplasm of the infected 178 cells appeared apple green when examined under a fluorescence microscope. 179

#### **180** Statistical analysis

181 R square (R<sup>2</sup>), mean, and standard deviation (SD) were determined, and figures were drawn
182 using GraphPad Prism version 8.4.3 for Windows (GraphPad Software, La Jolla, California, USA).
183 The McNemar test was carried out and 95% confidence interval (95% CI) calculated by SPSS
184 Statistic software version 18.0.

185

## 186 **Results**

# 187 Prevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients by

188 time

Using microNT assay and Architect IgG, and IFA for confirmation, anti-SARS-CoV-2 189 antibodies were detected in 124 (87.3%) of 142 COVID-19 patients from the first epidemic wave. 190 Eighty-eight percent (15 of 17) of the patients had antibody responses at 8 days after onset of 191 symptoms. Positivity rose further to 94.1% (16 of 17) at 15-21 days, 100% (19 of 19) at 22-30 192 193 days, and 97% (32 of 33) at 31-60 days after onset of symptoms (Fig 2). NT antibodies persisted for at least 8 months as found in all 7 participants with history of COVID-19, while IgG specific 194 to N protein was found in only 3 of these 7 cases. Nevertheless, the numbers of antibody-positive 195 cases detected by microNT assay and CLIA for IgG were not significantly different (McNemar 196 test; p = 0.65). On the other hand, the NT antibody titers were not well correlate with the IgG levels 197  $(R^2 = 0.6042)$  (Fig 3). 198

199

Fig 2. Antibody response in COVID-19 patients at different time points after onset of disease
 symptoms.

Fig 3. Correlation between NT antibody titers and Architect IgG indices in COVID-19 patients.

204

# 205 Prevalence of anti-SARS-CoV-2 antibodies in participants with

206 selected occupations

The early COVID-19 outbreak in Thailand showed that some occupations had higher risk of infection than did others. We conducted serosurveillance for anti-SARS-CoV-2 antibodies in 2113 participants with at-risk occupations (health personnel, airport officers, public transport drivers and workers in entertainment venues) as shown in Table 1. The serum samples from health personnel were collected during the three epidemic waves, while the others were collected from the first or second epidemic wave. The result showed that none of the 2113 participants had anti-SARS-CoV-2 antibodies, except for 3 (0.44%) of 682 workers from the entertainment venues.

214

#### 215 Table 1. Seroprevalence of anti-SARS-CoV-2 antibodies in participants with at-risk

216 occupations.

Jan – December 14, 2020 No. pos/	December 15, 2020 – March 31, 2021 No. pos/	April 1 – May 31, 2021 No. pos/	Subtotal		
No. tested	No. tested	No. tested			
0/187	0/13	0/272	0/472		
0/493	-	-	0/493		
0/455	0/11	-	0/466		
3/682	-	3/682 (0.44%) 95% CI = 0.08 - 1.29%			
	14, 2020           No. pos/           No. tested           0/187           0/493           0/455	14, 2020         - March 31, 2021           No. pos/         No. pos/           No. tested         No. tested           0/187         0/13           0/493         -           0/455         0/11	Jan – December 14, 2020         December 15, 2020 – March 31, 2021         April 1 – May 31, 2021           No. pos/         No. pos/         No. pos/           No. tested         No. tested         No. tested           0/187         0/13         0/272           0/493         -         -           0/455         0/11         -		

# 218 Prevalence of anti-SARS-CoV-2 antibodies in people at risk

We conducted serosurveillance in 1856 Thai people at risk by sharing the same workplaces
or living in the same community with COVID-19 cases. The investigation showed that 1.9% (11
of 574), 1.5% (6 of 388), and 7.5% (11 of 147) of people in Bangkok were seropositive for anti-
SARS-CoV-2 antibody during the three epidemic waves, respectively. In Chiang Mai, 1.3% (10
of 747) of participants were seropositive during the first epidemic wave; 7 of them provided
histories of having COVID-19 during the prior 8 months (Table 2).

- 225
- 226 Table 2. Seroprevalence of anti-SARS-CoV-2 antibodies in participants who shared

#### 227 workplaces or lived in communities with reported COVID-19 cases.

	Epidemic wave								
Province	Jan – December 14, 2020	December 15, 2020 – March 31, 2021	April 1 – May 31, 2021						
	No. pos/No. tested	No. pos/No. tested	No. pos/No. tested						
D 1 1	11/574 (1.9%)	6/388 (1.5%)	11/147 (7.5%)						
Bangkok	95% CI = $0.95 - 3.43%$	95% CI = $0.56 - 3.37%$	95% CI = 3.72 –13.40%						
	10/747 (1.3%)								
Chiang Mai	95% CI = 0.64 - 2.46%	-	-						
	21/1321(1.6%)	6/388 (1.5)	11*/147 (7.5%)						
Subtotal	95% CI = $0.98 - 2.43%$	95% CI = 0.56 – 3.37%	95% CI = 3.72 – 13.40%						

Total = 38/1856 (2.04%), 95% CI = 1.44 - 2.81%

228 \* 7 participants provided history of COVID-19 at 8 months previously

## 230 Serological profiles of anti-SARS-CoV-2 antibodies in participants at

## 231 **risk**

We display in Tables 1 and 2 the serological profiles of anti-SARS-CoV-2 antibodies in 232 233 3969 participants, grouped as 2113 people at risk by occupation (Table 1), and 1856 people at risk by sharing workplaces or living community with COVID-19 patients. Using microNT assay and 234 Architect IgG, followed by IFA validation, 41 of 3969 (1.0%) were seropositive for anti-SARS-235 236 CoV-2 antibodies. The number of seropositive cases detected by Architect IgG was slightly lower 237 than that detected by microNT, but not significantly different (McNemar test; p = 0.54). 238 Furthermore, the NT antibody titers were not well correlated with the IgG levels obtained by CLIA  $(R^2 = 0.5908)$  (Fig 4). 239

240

Fig 4. Correlation between NT antibody titers and Architect IgG indices in Thai people.

242

#### 243 **Prevalence of anti-SARS-CoV-2 antibody in travelers returning from**

244 high-risk areas

This study conducted serosurveillance in 553 Thai citizens returning after extended duties in countries with high-prevalence of SARS-CoV-2 infection between May and October 2020. Our results showed seroprevalences of 6.5 – 47.0% depending on the country (Table 3).

#### 249 Table 3. Seroprevalence of anti-SARS-CoV-2 antibodies in Thais returning from extended

#### 250 periods of work in high-risk countries.

Country	Date of blood collection	No. pos/No. tested (%)				
Ostar	May – Jun 2020	14/215 (6.5%) 95% CI = 3.55 – 10.93%				
Qatar	May – Juli 2020					
	Mary Jun 2020	101/215 (47.0%)				
Kuwait	May – Jun 2020	95% CI = 38.27 - 57.08%				
<u>C 1</u>	0.42020	36/77 (46.8%)				
Sudan	Oct 2020	95% CI = 32.75 - 64.72%				
Others	Jun – Oct 2020	4/46 (8.7%)				
Others	Jun – Oct 2020	95% CI = $2.28 - 22.36%$				

Total = 155/553 (28.0%), 95% CI = 23.79 - 32.80%

251

252

## 253 **Discussion**

We employed 3 serological techniques to detect anti-SARS-CoV-2 antibodies in this 254 cross-sectional surveillance study. The NT antibodies were directed against the neutralizing 255 epitopes present in the receptor-binding domain (RBD). N terminal domain (NTD), and S2 domain 256 in the S protein [11-15]; Architect IgG was directed against the N antigen which is a more 257 conserved protein [16, 17]. NT antibodies are markers of protective immunity, but IgG against N 258 protein is not. MicroNT assay and Architect IgG were used to investigate every serum sample, and 259 260 the result was concluded to be negative when both methods yielded concordant results. In the case of discordant results, IFA (which employed the test antigens from both the S and N proteins) was 261 used to resolve discordance. Overall, the numbers of seropositive participants determined by 262

263 microNT assay and Architect IgG were not significantly different. Nevertheless, NT antibody titers
264 were not well correlated with the IgG levels.

Our study in COVID-19 patients showed that 15 of 17 (88.2%) patients mounted a detectable antibody response 8-14 days after onset of symptoms. However, the prevalence increased to as high as 94-100% in the subsequent 45 days. In addition, we found that anti-SARS-CoV-2 antibodies persisted for at least 8 months in all 7 individuals who had a history of COVID-19, while Architect IgG to N protein did not last that long. This is similar to the findings of others who reported 8-month antibody persistence in mild SARS-CoV-2 infections [18] and up to one year in one study [19].

We investigated 3969 blood samples from multiple groups of participants between May 272 14, 2020 and May 21, 2021, the duration spanning two epidemic waves and part of the third wave. 273 274 Of 2113 participants with the at-risk occupations (472 health providers, 493 airport officers, 466 public transport drivers, and 682 workers in entertainment venues), only 0.14% (all 3 from the last 275 group) had detectable anti-SARS-CoV-2 antibodies. Furthermore, of 1856 participants who shared 276 workplaces or communities, only 38 (2.04%) were seropositive. Over time, the number of 277 participants in Bangkok who had anti-SARS-CoV-2 antibodies increased from 1.9 to 1.5 and 7.5% 278 279 during the 3 epidemic waves, respectively. Our seroprevalence data strongly supported the prevalence of infection reported by the MoPH, i.e., the cumulative numbers of 4237 cases with 60 280 deaths at the end of the first epidemic wave (from Jan to Dec 14, 2020), 28863 cases with 94 deaths 281 282 at the end of the second epidemic wave (from Dec 15, 2020 to Mar 31, 2021), and 159792 cases with 1031 deaths (from Apr 1 to May 31, 2021). 283

Thailand received worldwide recognition for keeping the first epidemic wave well controlled. During the first epidemic wave, cumulative case count per population was in the 10<sup>th</sup>

percentile of countries globally [20]. As part of the control policy, the government provided 286 treatment and hospitalization, quarantine, and laboratory diagnosis of SARS-CoV-2 infection at 287 no cost. The prevalence of infection during the wave peaked in March 2020, followed by a sharp 288 decline. None or less than 10 locally transmitted cases were detected daily from the middle of May 289 through the end of the first epidemic wave. In total, there were 4237 cases with 60 deaths by the 290 291 end of the first epidemic wave (December 14, 2020). The high seroprevalence (6.5 - 47%) in Thai citizens returning from abroad suggested the seriousness of the outbreaks in those regions. 292 293 Nevertheless, high infection rates may be partly due to sharing workplaces among these participants. 294

Management of non-pharmaceutical interventions in Thailand was efficient. No people 295 296 protested against wearing masks in public. They followed the suggestions on soft locked down, social distancing, working from home, and personnel hygiene. A vital success came from the 297 assistance of approximately one million village health volunteers who are part of the public health 298 299 system and worked nationwide since the time of H5N1 avian influenza. These volunteers assist 300 with health education, active case finding, and communication between health authorities and communities. For example, each volunteer is assigned to take care of approximately 10 houses. 301 Nevertheless, the occurrence of the second and third epidemic waves came very abruptly, from 302 introduction of the newer variants, the GH clade and the Alpha variant, respectively. We cannot 303 deny that these outbreaks due to illegal activities, including cross border movement of migrant 304 workers and gamblers. 305

Before the third epidemic wave trended down, the outbreak situation of SARS-CoV-2 became worse due to introduction of the Delta variant (that is more transmissible and virulent) to seed a fourth epidemic wave. The infection rate peaked in August 2021, when more than 20000

cases were reported daily for weeks before slowly declining. However, non-pharmaceutical
 intervention appears inadequate to control the Delta variant, and access to vaccines has not been
 easy. The MoPH first launched vaccinations for health providers in late February 2021.
 At present, seroprevalence studies in the Thai population will encounter difficulties in

differentiating between natural infection and vaccination. Nevertheless, our seroprevalence data validate the reported lack of circulation of SARS-CoV-2 in Thailand during the first year of the pandemic.

316

## 317 Acknowledgements

We thank Abbott Laboratories for providing Chemiluminescence test kits. We also thank Chinda Kanoksinsombat, Tipsuda Chanmanee, Rumporn Kularb, and Charlearnsak Thapyotha for laboratory assistance.

321

## 322 **References**

- 1. Sirilak S, editor. Thailand's experience in the COVID-19 response [Internet]. Ministry of
- Public Health, Thailand. Aug 2020 [Cited 2021 October 31]. Available from:

https://ddc.moph.go.th/viralpneumonia/eng/file/pubdoc/LDoc9.pdf.

2. Win A. Rapid rise of COVID-19 second wave in Myanmar and implications for the Western

- 327 Pacific region. QJM. 2020;113:856-57.
- 328 3. Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. New waves of COVID-19 in
- Thailand, Cambodia and Myanmar. Am J Intern Med. 2021;9: 114-20.

- 4. WHO Cambodia. Cambodia Coronavirus Disease 2019 (COVID-19) Situation Report #35.
- 331 2021 March 01 [Cited 2021 October 31]. Available from:
- https://www.who.int/cambodia/internal-publications-detail/covid-19-joint-who-moh-situation report-35.
- 334 5. Tribune B. First local cases of contagious Indian variant discovered among construction
- 335 workers in Lak si. Bangkok Tribune Online News Agency. 2021 May 21 [Cited 2021 October
- 336 31]. Available from: https://bkktribune.com/first-local-cases-of-contagious-indian-variant 337 discovered-among-construction-workers-in-lak-si/.
- Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al.
   Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proc Natl Acad
   Sci U S A. 2021;118:e2109229118.
- Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody
  responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine.
  2021;71:103561.
- Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A longitudinal study of
   SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and
   COVID-19 severity. Cell Mol Immunol. 2021;18:318-327.
- 347 9. Lerdsamran H, Prasertsopon J, Mungaomklang A, Klinmalai C, Noisamdaeng P, Sangsiriwut
- K, et al. Seroprevalence of antibodies to enterovirus 71 and coxsackievirus A16 among people
  of various age groups in a northeast province of Thailand. Virol J. 2018;15:158.
- 350 10. Lerdsamran H, Mungaomklang A, Iamsirithaworn S, Prasertsopon J, Prasert K, Intalapaporn P,
- et al. Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies,
- 352 Thailand. BMC Infect Dis. 2021;21:1213.

- 11. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The
   receptor-binding domain of the viral spike protein is an immunodominant and highly specific
   target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5:eabc8413.
- 12. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent
- neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science.
  2020;369:643-50.
- 13. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds
  to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369:650-55.
- 14. Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, Tan TH, et al. Amino acids 1055 to 1192 in
- the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing
- antibodies: implications for the development of vaccines and antiviral agents. J Virol.
   2005;79:3289-96.
- 365 15. Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic
  366 development. Nat Rev Microbiol. 2021;19:685-700.
- 367 16. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS-CoV-2: a Target for
  368 Vaccine Development. J Virol. 2020;94:e00647-20.
- 369 17. Negara MRM, Krissanti I, Pradini GW. Analysis of SARS-CoV-2 nucleocapsid protein
  370 sequence variations in ASEAN countries. Med J Indones. 2021;30:89-95.
- 18. Perez-Saez J, Zaballa ME, Yerly S, Andrey DO, Meyer B, Eckerle I, et al. Persistence of anti-
- 372 SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance.
- 373 Clin Microbiol Infect. 2021;27:1695.e7-12.

374	19. Haveri A, Ekström N, Solastie A, Virta C, Österlund P, Isosaari E, et al. Persistence of
375	neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol.
376	2021;51:3202-13.
377	20. Our World in Data. Thailand: Coronavirus Pandemic Country Profile. 2021 [Cited 2021

378 October 20]. Available from: <u>https://ourworldindata.org/coronavirus/country/thailand</u>.

379

	1280 <sub> </sub>										
	640-			00		000	0000	o	o		
	320-		0	0	0 <u>0 0</u> 0	00	00	000	T		
titer	160-	o		0	000	o	00000	00	00		
antibody titer	80-	o	т	o o o o	00000	<u> </u>	000000	000		o	
antib	40-	Т	ø	+		00	o o o o	000		00	
L N	20-	0	00	00000	00	o o o o	000000000000000000000000000000000000000	000000		00	
	10-	00		00	00	000	0	00	0	00	
	<10-	000000	o o o o	00	0		٥	00000	0		
	₀⊥										
Days after onset		0-3	4-7	8-14	15-21	22-30	31-60	61-90	91-101	>320	Total
Number of patients Number positive by NT (%) GMT		11 5 (45.5) 11.3	8 4 (50.0) 15.4	17 15 (88.2) 43.4	17 16 (94.1) 70.8	19 19 (100.0) 66.7	33 32 (97.0) 64.8	25 20 (80.0) 34.8	5 4 (80.0) 60.6	7 7 (100.0) 24.4	142 122 (85.9) 43.0
Number positive by Archited (%)	ct IgG	5 (45.5)	4 (50.0)	14 (82.4)	16 (94.1)	19 (100.0)	31 (93.9)	19 (76.0)	4 (80.0)	3 (42.9)	115 (81.0)
Number positive after IFA ve (%)	erification	5 (45.5)	4 (50.0)	15 (88.2)	16 (94.1)	19 (100.0)	32 (97.0)	21 (84.0)	5 (100.0)	7 (100.0)	124 (87.3)

Fig2

Architect IgG (S/C)	10 - 9 - 8 - 7 - 6 - 5 - 4 - 3 - 2 - 1 - 0 -	R <sup>2</sup> = 0.60				000 000 000 000 00 00 00 00 00 00 00 00				
- NT antibody titer Number of cases	<b>-</b> 1⊥	<10 20	10 15	<b>20</b> 32	<b>40</b> 12	<b>80</b> 24	<b>160</b> 15	<b>320</b> 13	<b>640</b> 11	- No. pos/Total (%) 122/142 (85.9)
Number positive by Architect I (%) Mean of index values (S/C)	lgG		10 (66.7) 1.9	30 (93.8) 3.8	11 (91.7) 4.8	23 (95.8) 5.2	15	13 (100.0) 7.4	11	115/142 (81.0) 4.4

Fig3




Fig4

